Anti-C-reactive protein (CRP) antibodies have been described in patients with systemic lupus erythematosus (SLE). We investigated the potential of the anti-CRP antibody as a marker for disease activity in SLE patients and as a predictor of progression to SLE in patients with incomplete lupus.
Methods
Immunoglobulin G anti-CRP antibody levels were measured using an enzyme-linked immunosorbent assay.
Results
Patients with incomplete lupus exhibited clinical and immunologic characteristics different from those in SLE patients: no serositis and alopecia, more common oral ulcers and arthritis, lower disease activity index, lower positivity for antinuclear and anti–double-strand DNA antibodies, and higher complement levels. Anti-CRP antibody levels were higher in SLE patients (35.6 [35.1] AU) than in patients with incomplete lupus (23.1 [25.8] AU, P = 0.016) and normal controls (21.0 [14.3] AU, P < 0.001). Anti-CRP antibody was significantly higher in SLE patients with arthritis and correlated with disease activity markers, including antichromatin antibody. However, no difference in anti-CRP antibody levels was observed between patients with incomplete lupus that progressed to SLE and those whose did not.
Conclusion
These data suggest that anti-CRP antibodies can neither be used as biomarkers in SLE nor predict SLE progression in patients with incomplete lupus.
ShererY, GorsteinA, FritzlerMJ, . Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum. 2004; 34: 501–537.
2.
VilaLM, MayorAM, ValentinAH, . Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus. Lupus. 2000; 9: 110–115.
3.
SwaakAJ, van de BrinkH, SmeenkRJ, . Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology (Oxford). 2001; 40: 89–94.
4.
LiQZ, ZhouJ, WandstratAE, . Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. Clin Exp Immunol. 2007; 147: 60–70.
5.
SuhCH, ChunHY, YeYM, . Unresponsiveness of C-reactive protein in the non-infectious inflammation of systemic lupus erythematosus is associated with interleukin 6. Clin Immunol. 2006; 119: 291–296.
6.
SuhCH, JeongYS, ParkHC, . Risk factors for infection and role of C-reactive protein in Korean patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2001; 19: 191–194.
7.
KimHA, JeonJY, AnJM, . C-reactive protein is a more sensitive and specific marker for diagnosing bacterial infections in systemic lupus erythematosus compared to S100A8/A9 and procalcitonin. J Rheumatol. 2012; 39: 728–734.
8.
FiroozN, AlbertDA, WallaceDJ, . High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. Lupus. 2011; 20: 588–597.
9.
Du ClosTW, ZlockLT, HicksPS, . Decreased autoantibody levels and enhanced survival of (NZB x NZW) F1 mice treated with C-reactive protein. Clin Immunol Immunopathol. 1994; 70: 22–27.
10.
KimHA, ChunHY, KimSH, . C-reactive protein gene polymorphisms in disease susceptibility and clinical manifestations of Korean systemic lupus erythematosus. J Rheumatol. 2009; 36: 2238–2243.
11.
JonsenA, GunnarssonI, GullstrandB, . Association between SLE nephritis and polymorphic variants of the CRP and FcgammaRIIIa genes. Rheumatology (Oxford). 2007; 46: 1417–1421.
12.
GaitondeS, SamolsD, Kushner I. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum. 2008; 59: 1814–1820.
13.
RobeyFA, JonesKD, SteinbergAD.C-reactive protein mediates the solubilization of nuclear DNA by complement in vitro. J Exp Med. 1985; 161: 1344–1356.
14.
BellSA, FaustH, SchmidA, . Autoantibodies to C-reactive protein (CRP) and other acute-phase proteins in systemic autoimmune diseases. Clin Exp Immunol. 1998; 113: 327–332.
15.
FigueredoMA, RodriguezA, Ruiz-YagueM, . Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome. J Rheumatol. 2006; 33: 1980–1986.
ShoenfeldY, Szyper-KravitzM, WitteT, . Autoantibodies against protective molecules–C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann N Y Acad Sci. 2007; 1108: 227–239.
18.
MeyerO.Anti-CRP antibodies in systemic lupus erythematosus. Joint Bone Spine. 2010; 77: 384–389.
19.
TanEM, CohenAS, FriesJF, . The 1982revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25: 1271–1277.
20.
BombardierC, GladmanDD, UrowitzMB, . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992; 35: 630–640.
21.
KimHA, JeonJY, ChoiGS, . The antichromatin antibodies can be useful as a diagnostic tool and disease activity marker of systemic lupus erythematosus in Koreans. Clin Immunol. 2008; 128: 277–283.
22.
RosenauBJ, SchurPH.Antibodies to C reactive protein. Ann Rheum Dis. 2006; 65: 674–676.
23.
ZunigaR, MarkowitzGS, ArkachaisriT, . Identification of IgG subclasses and C-reactive protein in lupus nephritis: the relationship between the composition of immune deposits and FCgamma receptor type IIA alleles. Arthritis Rheum. 2003; 48: 460–470.
24.
TanY, YuF, YangH, . Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions. Hum Immunol. 2008; 69: 840–844.
25.
O'NeillSG, GilesI, LambrianidesA, . Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2010; 62: 845–854.
26.
SjowallC, ZickertA, SkoghT, . Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. Arthritis Res Ther. 2009; 11: R188.
27.
SjowallC, BengtssonAA, SturfeltG, . Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther. 2004; 6: R87–R94.
28.
Zandman-GoddardG, BlankM, LangevitzP, . Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity. Ann Rheum Dis. 2005; 64: 1698–1702.
